Full Press Release Details
ROCKVILLE, Md., Nov. 6, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 6, 2014 - MacroGenics, Inc. (Nasdaq:
MGNX), a clinical-stage biopharmaceutical company focused on
discovering and developing innovative monoclonal antibody-based
therapeutics for the treatment of cancer, as well as autoimmune
disorders and infectious diseases, today announced that
pre-clinical data on MGD011, a humanized CD19 x CD3 Dual-Affinity
Re-Targeting (DART ) protein, will be highlighted
in a poster presentation at the 56th Annual Meeting of
the American Society of Hematology (ASH), to be held December 6-9,
2014 in San Francisco, CA.
MGD011 is designed to redirect T-cells to
eliminate CD19-expressing cells found in many hematological
malignancies and has been engineered to address half-life
challenges posed by other programs targeting CD19 and CD3.
Moreover, MGD011 and other DART molecules are manufactured using a
conventional antibody platform without the complexity of having to
genetically modify T cells from individual patients as required by
approaches such as chimeric antigen receptor (CAR) T cells.
MGD011 has a modified Fc domain, which allows for extended
pharmacokinetic properties and convenient dosing at a once-a-week
or longer interval. It is one of two new oncology-based DART
candidates for which MacroGenics intends to initiate clinical
"This represents another important milestone for our DART
platform," said Scott Koenig, M.D., Ph.D., President and CEO of
MacroGenics. "CD19-targeted therapies have generated much
excitement, and, based on our pre-clinical data, we believe that
MGD011 has great potential in the treatment of patients with
certain types of hematological malignancies. We look forward to
initiating clinical development in 2015."
MGD011, Humanized CD19 x CD3 DART Protein with Enhanced
Pharmacokinetic Properties, Demonstrates Potent T-Cell Mediated
Anti-Tumor Activity in Preclinical Models and Durable B-Cell
Depletion in Cynomolgus Monkeys Following Once-a-Week
Presenter: Liqin Liu, Ph.D., Senior Scientist
Session Name: 625. Lymphoma: Pre-Clinical -
Chemotherapy and Biologic Agents: Poster I
Presentation Date and Time: Saturday, December
6, 2014; 5:30 PM - 7:30 PM PT
Location: West Building, Level 1 (Moscone
Abstract Number: 1775
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal
antibody-based therapeutics for the treatment of cancer, as well as
autoimmune disorders and infectious diseases. The Company generates
its pipeline of product candidates from its proprietary suite of
next-generation antibody-based technology platforms. The
combination of MacroGenics' technology platforms and protein
engineering expertise has allowed the Company to generate promising
product candidates and enter into several strategic collaborations
with global pharmaceutical and biotechnology companies. For
more information, please see the Company's website at
www.macrogenics.com. MacroGenics and DART are registered
trademarks of MacroGenics, Inc.
Cautionary Note on Forward-Looking
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about the
Company's strategy, future operations, clinical development of the
Company's therapeutic candidates, milestone or opt-in payments from
the Company's collaborators, the Company's future expectations and
plans and prospects and other statements containing the words
"anticipate," "believe," "estimate," "expect," "intend," "may,"
"plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation and enrollment of future
clinical trials, expectations of expanding ongoing clinical trials,
availability and timing of data from ongoing clinical trials,
expectations for regulatory approvals, other matters that could
affect the availability or commercial potential of the Company's
product candidates and other risk factors described in the
Company's filings with the Securities and Exchange
Commission, including those discussed in the "Risk Factors" section
of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 20, 2014 and the
subsequent Quarterly Reports on Form 10-Q. In addition, the
forward-looking statements included in this press release represent
the Company's views as of the date hereof. The Company anticipates
that subsequent events and developments will cause the Company's
views to change. However, while the Company may elect to update
these forward-looking statements at some point in the future, the
Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing the Company's views as of any date subsequent to the